Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid. Issue 10 (8th December 2016)

• Record Type: Journal Article
• Authors: Honda, Yohji; Aikata, Hiroshi; Honda, Fumi; Nakano, Norihito; Nakamura, Yuki; Hatooka, Masahiro; Morio, Kei; Kobayashi, Tomoki; Fukuhara, Takayuki; Nagaoki, Yuko; Kawaoka, Tomokazu; Hiramatsu, Akira; Imamura, Michio; Kawakami, Yoshiiku; Chayama, Kazuaki
• Is Part Of: Hepatology research. Volume 47:Issue 10(2017)
• Page Start: 1053
• Page End: 1060
• Publication Date: 2016-12-08
• Subjects: bone metastasis -- HCC -- serum NTX -- skeletal‐related event -- zoledronic acid; Liver -- Diseases -- Periodicals; Liver Diseases -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1111/hepr.12844
• Languages: English
• ISSNs: 1386-6346

Abstract

Abstract: Aims: We retrospectively analyzed the clinical outcome and prognostic parameters in patients with hepatocellular carcinoma (HCC) and bone metastases who had received treatment with zoledronic acid (ZOL). Methods: Ninety‐nine HCC patients with bone metastases who had been treated with ZOL were enrolled in this retrospective cohort study. We analyzed the prognostic factors, including serum N‐telopeptide of type I collagen (NTX) levels, as bone metabolism markers. Results: The median overall survival (OS) time was 11.5 months. Child–Pugh grade A ( P = 0.004) and intrahepatic tumor stage (IHTS) T0–3 ( P = 0.010) correlated significantly with favorable OS. In 46 patients with grade A and T0–3, receiver operating characteristic curve analysis defined 16 nmol BCE/L serum NTX as the cut‐off level for median OS. Multivariate analysis identified baseline serum NTX <16 nmol BCE/L ( P = 0.045) as the only significant and independent determinant of OS. Conclusion: Low baseline serum NTX level correlated with favorable outcome in bone metastatic HCC patients with Child–Pugh grade A and IHTS T0–3 treated with ZOL.